The Public Citizen consumer group thinks the FDA has not adequately warned physicians and Zyprexa patients of the Zyprexa risks. Hyperglycemia, diabetes, and ketoacidosis have been reported amongst Zyprexa patients. Ketoacidosis, associated to Zyprexa adverse effects reports end up fatal in about 50% of the cases. The last time the Zyprexa labeling was updated in the U.S. the FDA only made a quick reference to the risk of Zyprexa diabetes and hyperglycemia in the middle of the adverse reactions section of Zyprexa labeling.

Zyprexa is linked to weight gain, diabetes, glucose problems, increased cholesterol, and increased triglycerides.

In a recent National Institute of Mental Health study, some disturbing facts about weight gain and Zyprexa were found:

Patients taking Zyprexa gained an average of 2 pounds per month.

30% of Zyprexa recipients gained 7% or more of their original weight during the study. Only 12% of the patients using the first-generation drug experienced a similar weight gain.

31% of Zyprexa recipients found the weight gain or metabolic effects so distressing that they chose to stop treatment, compared with a mere 3% of patients who discontinued a first generation drug for similar reasons.

As reported by the FDA in January of 2004:

FDA and Lilly notified healthcare professionals of revision to the WARNINGS section of labeling, describing the increased risk of hyperglycemia and diabetes in patients taking Zyprexa. FDA has asked all manufacturers of atypical antipsychotic medications, including Lilly, to add this Warning statement to labeling.

If you are suffering from any of the following conditions after taking this drug, you may need to seek help/advise.

• Diabetes
• Ketoacidosis
• Severe weight gain
• Diabetic coma
• Heart attack
• Hyperglycemia
• Neuroleptic Malignant Syndrome
• Pancreatitis
• Stroke
• Tardive Dyskinesia
• Seizures
• Gynecomastia